Addison’s and Cushing’s Disease Section 4.1 –...

If you’re managing patients with heart failure, you already know the medication landscape has evolved quickly over the past decade. From traditional volume management with furosemide to newer, guideline-driven therapies like sacubitril/valsartan and empagliflozin, staying up to d ...  Show more

This podcast episode breaks down diabetes “compelling indications” in a way that’s highly practical for nurses managing complex patients. It explains how comorbid conditions like cardiovascular disease, heart failure, and chronic kidney disease influence medication selection beyo ...  Show more

Contributor: Jorge Chalit-Hernandez, OMS3

Educational Pearls:

CYP enzymes are responsible for the metabolism of many medications, drugs, and other substances

In this episode, we discuss the evidence, safety, and place in therapy of Journavx® (suzetrigine), a newly approved analgesic with a unique non-opioid mechanism of action and additional considerations for its use. Key Concepts Suzetrigine is a first in its class NaV1.8 sodium cha ...  Show more

CardioNerds Dr. Rick Ferraro, Dr. Gurleen Kaur, and Dr. Maryam Barkhordarian discuss the evidence and data supporting SGLT inhibition for cardiovascular and kidney health outcomes with expert faculty Dr. Muthu Vaduganathan. They discuss the role of SGLT inhibitors in different po ...  Show more

The 2020 ACLS guidelines updated the dose for administration of Atropine and Dopamine for the treatment of unstable bradycardia. The signs & symptoms of unstable bradycardia. Atropine's new dose and maximum. The use of atropine when a patient is in a second degree type II or thir ...  Show more